Staphylococcus aureus NorA protein is a transmembrane multidrug efflux pump that confers low-level resistance to hydrophilic fluoroquinolones. The norA gene promoter is active in Escherichia coli HB101. We have examined the genetic basis of norA-mediated resistance in E. coli by introducing a wild-type norA gene into HB101 on plasmid pCL1921, pBR322, or pUC18 exhibiting copy numbers that spanned a 22-fold range. Increased ciprofloxacin resistance correlated with norA transcript levels seen by Northern (RNA) analysis. Thus, contrary to some reports, a wild-type norA gene confers fluoroquinolone resistance in E. coli in a copy-number-dependent fashion and does not require mutational activation. Interestingly, a multicopy pUC19norA derivative gave transformants exhibiting a range of resistance phenotypes. The norA gene of one transformant carried a single base deletion (ATACAAT to AACAAT; the deleted base is underlined) in the putative ؊10 Pribnow box resulting in a promoter down-regulatory mutation; a second plasmid had acquired a frameshift producing a null mutation at codon 112. These mutations override the dual resistance-growthinhibitory phenotype of high-copy-number norA plasmids. The results have implications for using the standard E. coli HB101 system to assess NorA function and potentially for plasmid-borne transmission of norA-mediated drug resistance.
4-Quinolones, and particularly fluoroquinolones such as ciprofloxacin and norfloxacin, are potent antimicrobial agents that act by inhibiting bacterial DNA synthesis (35) . Their primary target in Escherichia coli is DNA gyrase, the enzyme that catalyzes ATP-dependent DNA supercoiling (3) (4) (5) . Recent work indicates that DNA topoisomerase IV, responsible for chromosome decatenation, is likely a secondary target in E. coli (9, 13) . Fluoroquinolones are also active against gram-positive species such as Staphylococcus aureus (23) . Unfortunately, a major problem associated with quinolone use against S. aureus has been the rapid emergence of resistant strains (32) . Many staphylococcal strains are already resistant to methicillin, and there is a limited repertoire of effective drugs. This situation has prompted work aimed at understanding the mechanisms of fluoroquinolone resistance.
Three defined genetic loci in S. aureus have thus far been implicated in quinolone resistance (11) : gyrA and gyrB, encoding subunits of DNA gyrase (16, 29, 30) ; grlA (possibly allelic with flqA [33] ), encoding the ParC subunit of topoisomerase IV (2); and norA, which specifies a drug efflux pump (12, 20, 21, 34, 37) . There is good evidence that chromosomal mutation initially in grlA followed by an alteration in gyrA can confer high-level quinolone resistance (1) . However, the role of norA in resistance is less well defined. The norA gene was first isolated from a norfloxacin-resistant clinical isolate by screening of a library of chromosomal DNA in plasmid pBR322 for an ability to confer resistance on E. coli HB101, a norfloxacinsusceptible strain (11, 34) . The gene encodes a 388-residue protein which exhibits 12 putative transmembrane domains (12, 37) . NorA belongs to a family of transport proteins that includes the related Bmr multidrug transporter of Bacillus subtilis and Tet, the tetracycline resistance pump (15, 19, 20, 34) .
Initial studies suggested that norA is somehow activated by mutation in drug-resistant isolates. Thus, Oshita et al. attributed resistance of one strain to an Asp-362-to-Ala mutation in NorA (22) . Two other resistant strains were shown to carry norA promoter mutations that acted to upregulate NorA expression (12, 21) . During the course of studies of fluoroquinolone resistance in S. aureus, we isolated the norA gene from a ciprofloxacin-resistant clinical isolate, S. aureus SA47, by screening a plasmid library for drug resistance in E. coli HB101 (11, 34) . The gene was found to be identical to its counterpart in SA31, the matched parental drug-susceptible strain. This observation led us to examine in detail the molecular basis of norA-mediated resistance in E. coli and the parameters limiting the utility of this system for studies of norA function. We show that norA has a dual copy-number-dependent resistancegrowth-inhibitory phenotype that has both practical and biological implications.
MATERIALS AND METHODS
Bacterial strains and plasmids. Methicillin-resistant S. aureus strains SA31 and SA47 have been described previously (29) 
. Plasmids pBR322, pUC18, and pUC19 and phages M13mp18 and M13mp19 were from our laboratory collection; pCL1921 was from David Summers, University of Cambridge, Cambridge, United Kingdom; and pBluescript SKϩ was from Stratagene.
Drugs and enzymes. Ciprofloxacin was a generous gift from Bayer, Wuppertal, Germany. Norfloxacin and ampicillin were purchased from Sigma, Ltd. Restriction enzymes, exonuclease III from E. coli, T4 DNA ligase, Klenow fragment of E. coli DNA polymerase I, Taq polymerase, and S1 nuclease from Aspergillus oryzae were obtained from New England Biolabs.
Isolation of norA genes. Chromosomal DNA from S. aureus SA47 was isolated (17) , digested with HindIII, ligated into HindIII-digested pBR322, and used to transform E. coli HB101 (7). Bacteria were selected on Luria-Bertani (LB) plates containing 100 g of ampicillin per ml and 0.1 g of ciprofloxacin per ml. Plasmid pSS47 from one drug-resistant colony was purified (25) and characterized by restriction enzyme digestion. Plasmid pSS31, carrying the S. aureus SA31 norA gene, was obtained by colony hybridization (25) of a size-selected (4.8 to 5.5 kb) pBR322 library of SA31 HindIII fragments in HB101. The probe used was the pSS47 norA insert radiolabeled with [␣-32 P]dCTP (3,000 Ci/mmol; Amersham International) by random primer extension with the Multiprime DNA Labelling kit (Amersham International). Hybridization of Hybond N filters (Amersham) was carried out overnight at 60ЊC in 5ϫ SSC (1ϫ SSC is 0.15 M NaCl plus 0.015 M sodium citrate) containing 1.5% dried milk. High-stringency washes were performed at 60ЊC in 1ϫ SSC-0.1% sodium dodecyl sulfate (SDS). For norA PCR, 5ЈAGTGATGAATTCAAAGAAAAAATA (nucleotide positions Ϫ153 to Ϫ130 upstream of the start ATG, with an artificial EcoRI site at position Ϫ147) and 5ЈATCAATCATAATATTAAGCTTTAC (complementary to positions ϩ1198 to ϩ1221 with an artificial HindIII site at position ϩ1206) were used as primers. PCRs were carried out with S. aureus or Staphylococcus epidermidis chromosomal DNA as the template as previously described (29, 30) with the following modifications: 50 ng of template DNA was used and the annealing temperature was 50ЊC. Products were confirmed as norA by Southern blotting (28) .
NorA plasmids. Relative plasmid copy numbers in E. coli HB101 were determined by a rapid miniprep method (25) . Plasmid DNA was isolated from bacterial cultures in LB broth (3 ml) containing ampicillin (100 g/ml) grown with aeration at 37ЊC to an optical density at 600 nm of 0.9. After HindIII digestion and electrophoresis in 0.8% agarose, DNA bands were stained with ethidium bromide and photographed under UV illumination and relative intensities of norA fragments were determined by laser densitometry using the Macintosh Deskscan and Collage software packages. Plasmids pSL1000 and pSL1001 were obtained as follows. A 1.8-kb MaeII fragment bearing the norA47 gene was isolated from plasmid pSS47 and cloned into the ClaI site of plasmid pBR322. The resulting plasmid, pSL500, was digested at EcoRI and SphI sites flanking the norA gene, and the released insert was ligated into EcoRI-SphI-cut pUC19 ϩ , i.e., pUC19 carrying three tandem copies of the sequence 5ЈGCTTAATTAATTA AGC (specifying a stop codon in all three reading frames) cloned (downstream of the SphI site) into the HindIII site that had been filled in using Klenow fragment and the four dNTPs. Transformation of E. coli HB101 produced many ampicillin-resistant colonies, two of which yielded plasmids pSL1000 and pSL1001.
Northern (RNA) blotting. Total cellular RNA was isolated from S. aureus essentially by the method of Gustafson et al. (6) . Its concentration was determined from the A 260 , and its integrity was checked by electrophoresis in a 1.0% agarose gel. For Northern blots, total RNA (10 g per lane) was denatured in a solution containing glyoxal and dimethyl sulfoxide and separated by electrophoresis in a 1.2% agarose gel (18) . RNA was transferred to a Hybond N nylon membrane and hybridized with an 881-bp RsaI norA probe (nucleotide positions ϩ177 to ϩ1058) that had been labeled with [␣-32 P]dCTP by random priming. Hybridization was carried out at 42ЊC overnight in a solution containing 50% formamide, 5ϫ SSC, 5ϫ Denhardt's solution, 0.5% SDS, and 100 g of denatured salmon sperm DNA per ml. High-stringency washes were carried out as described above for Southern blotting prior to radioautography over several days at Ϫ70ЊC with intensifying screens.
DNA sequence analysis. Nucleotide sequences for both strands of the norA genes in plasmids pSS47 and pSS31 were determined by the dideoxy chain termination method (26) using the Sequenase version 2.0 DNA kit (U.S. Biochemicals) and [␣- 35 S]dATP (Amersham) on M13 and plasmid Bluescript SKϩ subclones, respectively. For sequencing of pSL1000 or pSL1001, an exonuclease III-S1 method was used on HindIII-SphI-cut plasmids to generate unidirectional nested 3Ј truncations of the norA gene as described in reference 23a. Only the recessed 3Ј end of the unique HindIII site downstream of norA is digested by exonuclease III: the protruding 3Ј terminus of the SphI site (3Ј of the HindIII site) is not attacked, thus protecting vector sequences. Briefly, HindIII-SphI-cut DNA (5 g) was digested with E. coli exonuclease III (200 U) at 17ЊC (reaction volume, 60 l). Samples (2.5 l) were removed at intervals of 30 s (for small deletions) or 2 min (for sequencing purposes) and added on ice to tubes containing S1 nuclease (4 U) in its reaction buffer (7.5 l). Treatment with S1 nuclease and Klenow fragment of DNA polymerase I, plasmid self-ligation, and transformation of E. coli HB101 were all as described in the Promega protocol. Plasmids with truncated norA genes were isolated and subjected to doublestranded DNA sequencing using the pUC19 reverse primer, 5ЈCAGGAAA CAGCTATGAC, or primers specific to internal norA sequences.
Bacterial growth inhibition. Ciprofloxacin MICs were determined by incubation on LB plates containing 100 g of ampicillin per ml for 20 h at 37ЊC. For norA-associated growth inhibition studies, equal inocula of HB101 plasmid transformants were added to LB broth (20 ml) containing 100 g of ampicillin per ml and incubated at 37ЊC with aeration. Bacterial growth was measured by optical density at 600 nm.
RESULTS
Cloning norA genes from S. aureus SA47 and SA31. We used the standard method of screening a pBR322 library of genomic HindIII fragments in E. coli HB101 to obtain the norA gene from S. aureus SA47, a highly ciprofloxacin-resistant clinical isolate with a ciprofloxacin MIC of 16 g/ml (29) . Plasmid pSS47, carrying a 5.2-kb HindIII norA insert, was isolated and when retransformed into HB101 was sufficient to confer ciprofloxacin resistance. DNA sequence analysis of an internal 2.7-kb SphI-KpnI fragment confirmed the presence of the norA gene (norA47) (Fig. 1) . We could not be sure from the literature that the same approach would be successful for SA31, the matched ciprofloxacin-susceptible (MIC, 1 g/ml) pretreatment parent to SA47. Therefore, plasmid pSS31 bearing the norA31 gene was isolated from a size-selected library of 4.8-to 5.5-kb HindIII fragments in pBR322 by colony hybridization with a radiolabeled norA probe.
Drug resistance and bacterial growth inhibition are copynumber-dependent norA phenotypes. To examine the roles of norA47 and norA31 in norA-mediated resistance, we compared the phenotypes of 5.2-kb norA HindIII fragments cloned into FIG. 1. DNA sequence of the norA gene isolated from ciprofloxacin-resistant S. aureus SA47. Putative Ϫ35 and Ϫ10 promoter regions are underlined, as is a Shine-Dalgarno (SD) consensus. Asterisks denote termination codons. The vertical arrow denotes a T in the promoter region that is altered to A or to G in two norA promoter mutants (10, 21) . Closed circles identify nucleotides deleted in the down-regulated norA genes carried by plasmids pSL1000 and pSL1001 (see the text). The deduced amino acid sequence of NorA47 is given below the nucleotide sequence. Numbers on the right indicate amino acid residues. (14) . These constructs were transformed into E. coli HB101, and their relative copy numbers were determined by quantitative agarose gel electrophoresis (see Materials and Methods). Consistent with published work for other E. coli strains, five independent experiments gave relative copy numbers for pCL1921, pBR322, and pUC18 of 1 to 2.2 to 22, ratios not significantly altered by the presence of norA inserts. The ciprofloxacin MICs for strains containing pCL1921, pBR322, and pUC18 vector DNA were in each case 0.005 g/ml. Insertion of the norA gene from SA47 increased the MIC from 0.005 to 0.15 (pCL1921norA), 0.20 (pBR322norA, i.e., pSS47), and 0.55 g/ml (pUC18norA). We were surprised that the same copy-number-dependent increases in resistance were seen with the norA31 insert, and this observation led us to sequence the norA31 structural gene and its promoter. The region was identical to that of norA47, suggesting that the wild-type norA gene is sufficient to confer resistance in E. coli. Furthermore, levels of expression of the 1.35-kb norA transcript in S. aureus SA31 and SA47 were similar (Fig. 2) . Exposure of SA47 to 0.25 g of ciprofloxacin per ml resulted in a small induction of norA transcripts. At this level of drug, growth of SA47 was not markedly impaired, and the strain's Ser-84-to-Leu GyrA resistance mutation appears to rule out secondary effects via gyrase inhibition. Although further work will be necessary to examine the role of inducible norA expression, changes in the primary structure of the norA gene itself do not appear to be a factor in resistance of strain SA47. Interestingly, we noticed that high-copy-number norA plasmids also displayed a novel growth-inhibitory phenotype (Fig.  3) . Growth was significantly impaired by the presence of the norA31 insert in pBR322 and especially in pUC18. The relevance of the linked resistance-growth-inhibitory phenotypes of norA genes in E. coli is considered later.
Instability of pUC19norA constructs in E. coli. During attempts to overexpress norA protein in E. coli for biochemical studies by exploiting constitutive expression from a high-copynumber plasmid, we noted that a pUC19norA construct, when assembled and used to transform HB101 to ampicillin resistance, generated transformants with the expected plasmid restriction map but exhibiting very different ciprofloxacin MICs. Of two clones selected for study, one bearing plasmid pSL1000 was inhibited by ciprofloxacin at 0.25 g/ml, whereas the other, containing plasmid pSL1001, was entirely susceptible, with a ciprofloxacin MIC of 0.005 g/ml. The differing ciprofloxacin MICs of these transformants were unexpected: we had anticipated uniform MICs of 0.55 g/ml as seen for the closely related plasmid pUC18norA (see the previous section).
Northern blot analysis was used to compare transcript levels in E. coli transformants containing pSL1000 and pSL1001 with those in transformants containing other plasmids bearing norA inserts (Fig. 4) . The 1.35-kb norA transcript was present in all norA transformants but was absent from HB101 containing pUC18. Transcript levels for pCL1921, pBR322, and pUC18 carrying the 5.2-kb HindIII norA increased with copy number (lanes 2 to 6). Plasmid pSL1000 produced resistance and transcript levels similar to those produced by pSS47 (lanes 5 and 9) . However, paradoxically, although HB101 containing pSL1001 was fully sensitive to quinolones, the cells displayed hyperexpression of norA (lanes 10). In a manner similar to that of previous studies of norA expression in S. aureus and E. coli (12, 21) , there was evidence of transcript processing and degradation. For our E. coli experiments, this is unlikely to have arisen from RNA degradation during isolation: intact 16S and 23S rRNA bands were present in the RNA samples used (Fig. 4a) .
Frameshift mutations in the pUC19norA gene and its promoter. The sequence of the pSL1000 norA gene and its promoter was identical to that in pSS47 except for one nucleotide change: a deletion of the T (underlined) in the putative Pribnow box sequence at Ϫ10 altering the sequence from ATA CAAT to AACAAT (Fig. 1 ). There were no changes in the coding region. DNA sequence analysis of plasmids pSS31, pCL1921norA, pUC18norA, and pSL500 showed that they all retained the wild-type promoter region (data not shown). The SL1001 norA sequence was identical to that of pSS47 except for a deletion of a C nucleotide at position 328 in the coding sequence (Fig. 1) . This frameshift mutation (the deleted nucleotide is underlined) converted the reading frame from ATG CCT GGT GTG ACA (Met-109 Pro Gly Val Thr) to ATG CTG GTG TGA (Met-109 Leu Val Stop). pSL1001 norA had the wild-type promoter sequence. To determine if the pSL1001 The norA gene isolated from S. aureus SA31 was used. OD 600 , optical density at 600 nm.
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norA-MEDIATED FLUOROQUINOLONE RESISTANCE 1667 on September 7, 2017 by guest http://aac.asm.org/ frameshift generates a null mutation, a series of pSL1000 derivatives bearing progressive 3Ј truncations of the norA gene were obtained by exonuclease III-nuclease S1 digestion (see Materials and Methods). Removal of up to 13 residues of the highly charged C terminus of NorA could be tolerated with full retention of drug resistance: truncations beyond Ile-375 into the putative 12th transmembrane helix resulted in loss of function, implying that the termination codon at position 112 of pSL1001 norA produces a truncated inactive NorA protein.
Thus, pUC19norA plasmids acquire frameshift mutations generating a range of resistance phenotypes.
DISCUSSION
Plasmid studies with E. coli have played a pivotal role in both the discovery and the functional analysis of the S. aureus norA gene (10, 12, 21, 34, 37) . We show in this paper that plasmidborne wild-type norA genes confer ciprofloxacin resistance in E. coli in a manner critically dependent on plasmid copy number. The resistance mechanism in E. coli involves enhanced transcription and does not require mutational activation of the norA gene or its promoter. The activity of the wild-type norA gene in E. coli has also been observed recently by Ng et al. (21) . Thus, the ability to clone norA in E. coli is not informative about the likely contribution of norA to resistance in S. aureus. This result is important because norA is normally present in many (and perhaps all) strains of S. aureus; has a homolog in other staphylococcal species, including S. epidermidis (28a, 36) ; and thus will be encountered frequently during screening for resistance in E. coli. Although there were no differences in the primary sequence of norA in SA47 and SA31, our work with E. coli could not rule out the possibility of norA upregulation in S. aureus SA47. Two examples of constitutive upregulation due to norA promoter mutations are already known (Fig. 1) , and recent elegant work (10) has described a mutation in S. aureus unlinked to norA that confers quinolone-inducible norA expression. Northern analysis of SA31 and SA47 showed no differences in basal norA expression, but ciprofloxacin induced a severalfold increase in expression in SA47 that could contribute to resistance (Fig. 2) . Further work will be needed to examine these aspects of norA function in S. aureus.
Aside from its use in direct selection for norA genes from clinical isolates, the E. coli system offers the attractive possibility of expressing NorA protein at high levels for biochemical work. So far there have been no reports of successful expression and purification of NorA protein. During the construction of a pUC19norA derivative for expression-deletion analysis, we observed that its propagation in E. coli led to the spontaneous acquisition of frameshift mutations in the norA gene generating transformants with a range of resistance phenotypes. One pUC19norA plasmid, pSL1000, conferring intermediate ciprofloxacin resistance and norA transcript levels, had a wild-type norA gene that had undergone deletion of the first T in the TACAAT Pribnow box of the promoter, generating the sequence AACAAT. The T at the Ϫ10 position is highly conserved among bacterial promoters: its mutation to A has been examined in other systems and is known to produce defective transcription initiation (24, 38) . The mutation did down-regulate transcription: norA transcript levels for pSL1000 were much lower than those arising from a second pUC19norA isolate, pSL1001 (Fig. 4) . The latter plasmid had the wild-type norA promoter but had acquired a norA frameshift producing a termination signal (and null mutation) immediately after codon 111 (Fig. 1) . Production of a truncated nonfunctional NorA protein would explain the quinolone sensitivity of HB101 (pSL1001) despite very high norA transcript levels (Fig.  4 ). It appears that high-copy-number norA plasmids are unstable in E. coli, leading to the selection of spontaneous frameshift mutations in norA. This phenotype has not been previously reported, and it imposes limits on the utility of the widely used E. coli HB101 system for identification, overexpression, and functional dissection of candidate norA resistance genes from S. aureus.
Our data indicate that modest upregulation of norA expression through promoter mutations or through plasmid copy number can be tolerated in E. coli whereas high-level expression from pUC19-based plasmids is selected against. It is plausible that this selection involves escape from the growth inhibition that we observed for high-copy-number norA plasmids (Fig. 3) . Whatever its origin, the potential genetic instability of norA plasmids must be borne in mind when norA is manipulated for expression work with E. coli. Plasmid pSL1000 produces norA transcript levels similar to those of pSS47 (Fig. 4) , is stable in E. coli, and should facilitate deletion-expression studies. We have used it to show that in a manner similar to FIG. 4 . norA expression in E. coli HB101. Total RNA, purified from E. coli HB101 transformed with various norA plasmids, was separated on a denaturing formamide gel (a) and hybridized with a norA probe (b). The lanes contain RNA from HB101 (lane 1) or HB101 transformed with pCL1921norA31, pCL1921norA47, pBR322norA31, pBR322norA47, pUC18norA31, pUC18 (control), pSL500, pSL1000, or pSL1001 (lanes 2 to 10, respectively). The positions of RNA size markers are shown on the left. that of the tetracycline resistance pump (27) , an intact 12th transmembrane sequence in NorA is necessary for activity.
Finally, norA-E. coli is one of the few systems in which fluoroquinolone resistance can be plasmid mediated and exert a dominant phenotype. By contrast, resistance due to gyrA requires a mutation and is recessive (8) . In principle, plasmid capture of a wild-type norA gene could allow horizontal transmission of quinolone resistance in nature, which would be a worrying development. Surprisingly, despite intensive clinical use of fluoroquinolones over a substantial period, there has been only one report (thus far unsubstantiated) of a resistant isolate bearing a norA plasmid (31; reviewed in reference 23). This may simply reflect the poorly studied molecular epidemiology of norA-promoted resistance. Alternatively, multicopy norA plasmids by inhibiting bacterial growth may be disadvantageous in vivo and rarely selected.
